EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEV®) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Corona Virus Infection
- Coronaviridae Infections
- Nidovirales Infections
- Respiratory Tract Diseases
- Respiratory Tract Infections
- RNA Virus Infections
- SARS (Severe Acute Respiratory Syndrome)
- Virus Diseases
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04822818
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Jacques CADRANEL, PUPH Assistance Publique - Hôpitaux de Paris